Time to go All-In on Celsion?
Celsion (CLSN) is a great story stock. It recently announced their Phase III trial results for liver cancer will be released by the end of January 2013. This will be a top-line release of a multinational, double-blind, placebo-controlled study of primary liver cancer. The results could make or break the company as its future pipeline is dependent on ThermoDox succeeding.
This upcoming catalyst is likely to have a huge impact on the company's valuation. The company has a current market cap of $287 million, but this will likely be drastically different by the end of the month. The CEO of Celsion has stated that this liver cancer treatment will have the potential to generate yearly revenues of $1 billion.
Mastery Bottom Line
Look for a good entry point before betting the farm on CLSN. Shares could dip down to touch the 50 day MA due to some investors not wanting to risk holding through the FDA results. A $7 - $7.50 share price would provide a great buying opportunity.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Asian Property Prices Are Falling "As If There's A Global Financial Crisis" | ZeroHedge
- The Great Deformation | ZeroHedge
- Small Cap Relative Strength | Financial Sense
- Saudi King Warns ISIS "Will Reach Europe In One Month, US In Two" | ZeroHedge
- Inside the Market’s Mind: Debt, Growth and Politics | Financial Sense
- Sunday Matinee at Chess Cinemas | iBankCoin.com
- Ramp Up Your Weekly Market Preparation | iBankCoin.com
The most relevant financial news and articles from the Internets
- Putin's Trump Card In Ukraine: Winter Is Coming | Business Insider
- Lesotho PM heading home after 'coup' | Business Insider
- Why J.C. Penney's New Brooklyn Store Is Only Part of the Revival | TheStreet.com
- Japanese Porn Queens Raise Thousands Of Dollars For Aids... | Business Insider
- Liverpool are back to their best, says Rodgers | Business Insider
- Putin urges Europeans to have 'common sense... | Business Insider
- US forces conduct operation in Somalia: Pentagon | Business Insider